Integrity Applications announced that it has met with the FDA to discuss clinical trial protocol for its GlucoTrack Model DF-F.
GlucoTrack is a non-invasive device designed for measuring glucose levels of people with Type 2 diabetes or at risk of developing diabetes.
The company submitted pre-submission documents to the FDA in August, including the U.S. clinical trial protocol.
Integrity expects to begin clinical trials in the United States in early 2016. — Michael Cipriano